heiDATA

Metrics

191,583 Downloads

Featured Dataverses

In order to use this feature you must have at least one published dataverse.

Publish Dataverse

Are you sure you want to publish your dataverse? Once you do so it must remain published.

Publish Dataverse

This dataverse cannot be published because the dataverse it is in has not been published.

Delete Dataverse

Are you sure you want to delete your dataverse? You cannot undelete this dataverse.

File Type: Document

31 to 40 of 968 Results

Vardarli_Supplemental Table legends.docx Nov 25, 2023 - Risk and incidence of endocrine immune related adverse effects under checkpoint inhibitor mono or combination therapy in solid tumors: a meta-analysis of randomized controlled trials [data] MS Word - 13.3 KB - MD5: 7c350502f033008bfdfc0f43b17b6199 Supplemental Table legends
Vardarli_Supplemental Figure legends.docx Nov 25, 2023 - Risk and incidence of endocrine immune related adverse effects under checkpoint inhibitor mono or combination therapy in solid tumors: a meta-analysis of randomized controlled trials [data] MS Word - 13.8 KB - MD5: ba86a43da420eaea333e3062bed27e31 Supplemental Figure legends
Vardarli_Suppl. Table 9.pdf Nov 25, 2023 - Risk and incidence of endocrine immune related adverse effects under checkpoint inhibitor mono or combination therapy in solid tumors: a meta-analysis of randomized controlled trials [data] Adobe PDF - 216.7 KB - MD5: 78f6d13d435b94fe3733e03fdaf77c63 Suppl. Table 9. Trim-and-fill results for trials investigating adrenal insufficiency any grade after immune related checkpoint inhibitor therapy in solid tumors, n= 80 trials.
Vardarli_Suppl. Table 8.pdf Nov 25, 2023 - Risk and incidence of endocrine immune related adverse effects under checkpoint inhibitor mono or combination therapy in solid tumors: a meta-analysis of randomized controlled trials [data] Adobe PDF - 218.9 KB - MD5: e32fa8cb72081403d574d4d1d280e827 Suppl. Table 8. Trim-and-fill results for trials investigating hypophysitis/hypopituitarism grade 3-5 after immune related checkpoint inhibitor therapy in solid tumors, n= 80 trials.
Vardarli_Suppl. Table 7.pdf Nov 25, 2023 - Risk and incidence of endocrine immune related adverse effects under checkpoint inhibitor mono or combination therapy in solid tumors: a meta-analysis of randomized controlled trials [data] Adobe PDF - 216.5 KB - MD5: c1e3211bc08d5e1fd11cb1ca68248762 Suppl. Table 7. Trim-and-fill results for trials investigating hypophysitis/hypopituitarism any grade after immune related checkpoint inhibitor therapy in solid tumors, n= 80 trials.
Vardarli_Suppl. Table 6.pdf Nov 25, 2023 - Risk and incidence of endocrine immune related adverse effects under checkpoint inhibitor mono or combination therapy in solid tumors: a meta-analysis of randomized controlled trials [data] Adobe PDF - 220.7 KB - MD5: 30371284a775d08e7044c09b78aaeace Suppl. Table 6. Meta-regression for trials investigating hyperthyroidism any grade after immune related checkpoint inhibitor therapy in solid tumors, n= 80 trials.
Vardarli_Suppl. Table 5.pdf Nov 25, 2023 - Risk and incidence of endocrine immune related adverse effects under checkpoint inhibitor mono or combination therapy in solid tumors: a meta-analysis of randomized controlled trials [data] Adobe PDF - 220.6 KB - MD5: 09b0b7b7245dcb116eb15df62fdef98d Suppl. Table 5. Meta-regression for trials investigating hypothyroidism any grade after immune related checkpoint inhibitor therapy in solid tumors, n= 80 trials.
Vardarli_Suppl. Table 4.pdf Nov 25, 2023 - Risk and incidence of endocrine immune related adverse effects under checkpoint inhibitor mono or combination therapy in solid tumors: a meta-analysis of randomized controlled trials [data] Adobe PDF - 257.8 KB - MD5: d6acaa2141ff4cf50ded0d6820579aea Suppl. Table 4. Frequencies of various parameters in included trials, n= 80 trials.
Vardarli_Suppl. Table 3.xlsx Nov 25, 2023 - Risk and incidence of endocrine immune related adverse effects under checkpoint inhibitor mono or combination therapy in solid tumors: a meta-analysis of randomized controlled trials [data] MS Excel Spreadsheet - 116.7 KB - MD5: 7b97c14d958dffb9cb3347b48fd10fba Suppl. Table 3. Study characteristics of randomized controlled trials investigating endocrine adverse effects any grade and grade 3-5 after immune related checkpoint inhibitor monotherapy or combination therapy in solid tumors. NSCLC, Non-small cell lung cancer; LD-SCLC, Limited...
Vardarli_Suppl. Table 2.pdf Nov 25, 2023 - Risk and incidence of endocrine immune related adverse effects under checkpoint inhibitor mono or combination therapy in solid tumors: a meta-analysis of randomized controlled trials [data] Adobe PDF - 363.9 KB - MD5: 7c1640658f8d06736e3dad712a927841 Suppl. Table 2. Search strategies for randomized controlled trials investigating endocrine adverse effects any grade and grade 3-5 after immune related checkpoint inhibitor monotherapy or combination therapy in solid tumors.

Vardarli_Supplemental Table legends.docx

Nov 25, 2023 - Risk and incidence of endocrine immune related adverse effects under checkpoint inhibitor mono or combination therapy in solid tumors: a meta-analysis of randomized controlled trials [data]

MS Word - 13.3 KB -

Supplemental Table legends

Vardarli_Supplemental Figure legends.docx

MS Word - 13.8 KB -

Supplemental Figure legends

Vardarli_Suppl. Table 9.pdf

Adobe PDF - 216.7 KB -

Suppl. Table 9. Trim-and-fill results for trials investigating adrenal insufficiency any grade after immune related checkpoint inhibitor therapy in solid tumors, n= 80 trials.

Vardarli_Suppl. Table 8.pdf

Adobe PDF - 218.9 KB -

Suppl. Table 8. Trim-and-fill results for trials investigating hypophysitis/hypopituitarism grade 3-5 after immune related checkpoint inhibitor therapy in solid tumors, n= 80 trials.

Vardarli_Suppl. Table 7.pdf

Adobe PDF - 216.5 KB -

Suppl. Table 7. Trim-and-fill results for trials investigating hypophysitis/hypopituitarism any grade after immune related checkpoint inhibitor therapy in solid tumors, n= 80 trials.

Vardarli_Suppl. Table 6.pdf

Adobe PDF - 220.7 KB -

Suppl. Table 6. Meta-regression for trials investigating hyperthyroidism any grade after immune related checkpoint inhibitor therapy in solid tumors, n= 80 trials.

Vardarli_Suppl. Table 5.pdf

Adobe PDF - 220.6 KB -

Suppl. Table 5. Meta-regression for trials investigating hypothyroidism any grade after immune related checkpoint inhibitor therapy in solid tumors, n= 80 trials.

Vardarli_Suppl. Table 4.pdf

Adobe PDF - 257.8 KB -

Suppl. Table 4. Frequencies of various parameters in included trials, n= 80 trials.

Vardarli_Suppl. Table 3.xlsx

MS Excel Spreadsheet - 116.7 KB -

Suppl. Table 3. Study characteristics of randomized controlled trials investigating endocrine adverse effects any grade and grade 3-5 after immune related checkpoint inhibitor monotherapy or combination therapy in solid tumors. NSCLC, Non-small cell lung cancer; LD-SCLC, Limited...

Vardarli_Suppl. Table 2.pdf

Adobe PDF - 363.9 KB -

Suppl. Table 2. Search strategies for randomized controlled trials investigating endocrine adverse effects any grade and grade 3-5 after immune related checkpoint inhibitor monotherapy or combination therapy in solid tumors.

Add Data

Share Dataverse

Link Dataverse

Reset Modifications